Mechanism by which the Grp94 molecular chaperone folds insulin-like growth factors

Grp94分子伴侣折叠胰岛素样生长因子的机制

• 批准号: 10246944
• 负责人: Timothy Oliver Street
• 金额: $ 39.83万
• 依托单位: BRANDEIS UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-01 至 2024-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10246944
• 关键词: ATP Hydrolysis; Antineoplastic Agents; Area; Attention; Behavior; Binding Sites; Biological; Biotechnology; Cells; Client; Clinical Trials; Collaborations; Complex; Cytosol; Detection; Disease; Dissociation; Disulfides; Drug Targeting; Endoplasmic Reticulum; Environment; Family; Goals; Golgi Apparatus; Growth Factor; Health; Heat-Shock Proteins 70; Hormones; Human; IGF1 gene; IGF2 gene; In Vitro; Individual; Insulin; Link; Malignant Neoplasms; Measurement; Mitochondria; Molecular Chaperones; Molecular Conformation; Molecular Structure; Non-Insulin-Dependent Diabetes Mellitus; Oncogenic; Pathology; Peptides; Process; Production; Proinsulin; Property; Proteins; Recording of previous events; Research; Role; Somatomedins; Structure of beta Cell of islet; System; Testing; Time; Universities; Work; Yeasts; analog; improved; inhibitor/antagonist; innovation; insulin secretion; member; novel; peptide hormone; protein folding; single-molecule FRET

The endoplasmic reticulum (ER) chaperone Grp94 is required for the correct folding and secretion of insulin-like growth factors (IGF), but the underlying mechanism is not understood. Our goal is to discover how Grp94 assists the folding of IGF proteins. Grp94 is a member of the Hsp90 chaperone family, which require ATP- driven conformational cycling to chaperone their “client proteins”. Many oncogenic proteins depend on Hsp90 for their function. As a result, ATP-competitive inhibitors of Hsp90 have been extensively investigated as anti- cancer drugs. Although cytosolic Hsp90s were the first intended targets of inhibitors in clinical trials, Grp94 is receiving increasing attention as a drug target. Grp94 can receive clients from BiP, the Hsp70-family chaperone in the ER. Through a chance discovery, we have found that the combination of BiP and Hsp90 inhibitors locks Grp94 in a novel conformation, a state apparently poised for client transfer from BiP to Grp94. Client transfer from BiP to Grp94 requires two sequential steps: handover of the client from BiP to Grp94, followed by BiP dissociation from the ternary complex. Our first hypothesis is that Hsp90 inhibitors block both steps: Hsp90 inhibitors stall Grp94 and BiP in a client transfer state because ATP-dependent conformational changes of Grp94 are required to handover the client from BiP and then displace BiP from Grp94. We will test this hypothesis with IGF2, as we have discovered that this Grp94 client also has a well-defined BiP binding site. Aim1: Determine whether ATP-dependent conformational changes of Grp94 cause BiP to handover a bound client protein, and whether Hsp90 inhibitors disrupt this client-transfer function. Aim2: Determine whether ATP- dependent conformational changes of Grp94 are required to actively displace BiP from Grp94. Aims 1&2 will test a unified mechanism that can explain how Hsp90 inhibitors disrupt Grp94 function, but does not explain what essential chaperoning function is provided by BiP and Grp94 for IGF proteins. We have discovered that IGF2 forms dynamic oligomers. Similar to other peptide hormones that are known to oligomerize, this self-association may enable IGF2 to be effectively concentrated and packaged prior to its export to the Golgi. Despite a plausible biological role for IGF2 oligomerization, we have also observed that IGF2 can transition from dynamic reversible oligomers to irreversible aggregates. Thus, our second hypothesis is that the essential chaperoning function of BiP and Grp94 is to maintain a dynamic oligomerization state of IGF2. This idea is tested in Aim3: Determine the influence of Grp94 and BiP on the oligomerization properties of ProIGF2.

内质网（ER）伴侣蛋白Grp94是蛋白质正确折叠和分泌所必需的